A neuroimmune, axis-regulated control disorder defined by D > R → persistence load exceeding reset capacity → recovery-phase termination failure across layers
Author: Michael Daniels · Framework: GLA · 3.0 · Date: March 22nd 2026 · Systems-level mechanistic interpretation (not medical advice or a treatment recommendation).
Thank you to everyone who has taken the time to read, question, and engage with this work. The GLA model is currently in a v3.0 state.
The most important change from v2.9 is not a new disease model, but a refinement in how the hinge is described biologically. In GLA v3.0, the hinge is defined functionally first, not molecularly first. Earlier versions were useful because they enforced hinge singularity and formalized the core acquisition condition:
ME/CFS becomes self-sustaining when unresolved persistence exceeds reset capacity during recovery:
D > R
This remains unchanged in v3.0.
What changed in v3.0 is not the acquisition condition, but the level of biological description surrounding it. Earlier versions could make the hinge appear too closely tied to a single molecular checkpoint. GLA v3.0 broadens the biological context around the hinge without changing the hinge itself.
The hinge remains the singular functional transition in which unresolved persistence exceeds reset capacity during recovery:
D > R
Biologically, this appears as persistent recovery-phase membrane-reset non-closure.
The broader Endoplasmic Reticulum (ER) regulatory field helps explain how repeated physiological stress is converted into instability, accumulated as overlap, and carried forward as duration debt. It describes the control environment that drives the system toward hinge engagement; it does not define a second hinge.
This broader ER regulatory field is best understood as a control environment influencing:
• recovery-phase timing
• signal termination
• reset stability
Relevant biological features within this broader control environment include:
• ER membrane microdomains
• σ1R (sigma-1 receptor) chaperone systems
• IP₃ receptor (IP3R) channel clusters
• ER–mitochondrial contact sites (MAMs)
• lipid–cholesterol microdomain organization
• ER–Golgi trafficking and N-linked glycan processing
The ER regulatory field does not replace the hinge. It helps explain how repeated physiological stress is converted into instability, accumulated as overlap, and expressed as duration debt during recovery.
In other words, it explains how the system is driven toward hinge engagement, not why multiple hinges exist.
The acquisition condition remains singular:
D > R
GLA v3.0 clarifies that this architecture should not be reduced to a single tissue or pathway. The same control failure can be read across multiple biological levels:
• Visible expression → endothelial and skeletal-muscle execution surfaces
• Stability expression → membrane microdomain organization and signaling precision
• Authorization expression → reset-permissive processes within the broader ER regulatory field
• System-wide spread → neuroimmune and autonomic coupling
These are not competing disease explanations.
They are different biological readings of the same recovery-control failure.
For clarity, GLA v3.0 distinguishes three faces of the same failure:
• visible face → where dysfunction becomes physiologically apparent
• stability face → where signal organization and control precision degrade
• authorization face → where recovery-phase reset becomes non-permissive
The Gut–Liver–Brain (Autonomic) Axis
Within the GLA framework, ME/CFS is best understood as a:
Neuroimmune, axis-regulated recovery-termination disorder
In this model:
• the gut determines input load (immune and metabolic signals)
• the liver buffers, routes, and amplifies those signals
• the autonomic nervous system governs timing, coordination, and recovery-phase transitions
This axis continuously regulates:
• input load
• signal gain and routing
• recovery-phase timing
• effective reset capacity (R)
When the axis becomes dysregulated:
1. Input increases (gut-derived signals, immune activation)
2. Processing weakens (reduced hepatic buffering and routing)
3. Timing destabilizes (autonomic control becomes noisy or mistimed)
This drives vertically integrated instability across the system:
• visible dysfunction at execution surfaces
• loss of signaling precision and membrane stability
• reduced reset permissiveness during recovery
• amplified neuroimmune and autonomic coupling
Over time:
Unresolved persistence exceeds reset capacity → D > R
At this point, the system transitions from a stress-responsive state to a self-sustaining pathological attractor.
Within the GLA framework, ME/CFS is not defined by a single tissue pathology. It is best understood as:
A neuroimmune, axis-regulated recovery-termination disorder in which the gut–liver–brain (autonomic) axis influences whether physiological stress is resolved or carried forward across recovery cycles.
• The endothelium and skeletal muscle act as primary execution surfaces
• The core failure is persistent recovery-phase non-closure
• The defining feature is failure of signal termination, not failure of activation
• The hinge remains singular and is defined by D > R
A formal mathematical framework—developed with AI-assisted systems modeling—has been constructed to describe this architecture, including:
• persistence acquisition under the D > R condition
• recovery-phase failure dynamics
• recovery-phase persistence dynamics, hysteresis, and attractor stabilization
There are several supporting documents and rule sets from v2.6 through v3.0 that are not yet fully integrated into the website. These were used to maintain internal consistency and prevent conceptual drift while developing the framework across increasingly detailed biological layers.
I am deeply grateful to the researchers who have continued to investigate ME/CFS as a serious biological illness, particularly during periods when the field was often framed in psychological terms.
The quality and direction of recent work — across vascular biology, immune persistence, membrane regulation, recovery physiology, and post-viral disease — has been extraordinary. This framework is built in dialogue with that effort.
Thank you.
Figure 1 — GLA v3.0 System Map: Axis-Regulated Biological Expressions of Recovery-Phase Failure in ME/CFS
Figure 1. ME/CFS is modeled here as a neuroimmune, axis-regulated recovery-termination disorder with a singular persistence condition: D > R. The gut–liver–brain (autonomic) axis regulates system state across multiple biological expressions of the same failure. Endothelium and skeletal muscle serve as primary execution surfaces where dysfunction becomes physiologically visible. Membrane microdomains reflect the stability face of the system, while reset-permissive processes within the broader ER regulatory field reflect the authorization face. The ER regulatory field is shown here as the broader authorization context, not as a second hinge. Persistence emerges when activity fails to terminate during recovery, so unresolved duration exceeds effective reset capacity and D > R, resulting in a self-sustaining pathological state.
GLA v2.9+ — Canonical framework
Current authoritative mechanistic models defining PEM as a recovery-phase failure.
GLA v2.9+ — Modules
Focused modules expanding Tier 1 hinge logic and Tier 2 timing architecture.
Framework documents
Core architecture and definitions that anchor the GLA model.
Papers
Longer, paper-format documents (reader narrative + figures).
Modules (v2.1 → v2.6)
Modular “building blocks” used across the site. Organized by version and topic.
SMPDL3B phenotype frameworks
Phenotype-specific models (shedding vs deficient) and the mechanistic chain framework.
System modulators & control-state modifiers
Documents that shape interpretation of the core framework and control-state behavior.